ACRS - NASDAQ
Aclaris Therapeutics, Inc.
$4.42
-4.5%Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
At a Glance
Live SnapshotAclaris Therapeutics, Inc. Management Team
Mr. James Loerop
Chief Business Officer
Compensation
$570,000
Mr. Kevin Balthaser
Chief Financial Officer
Compensation
$675,360
Dr. Joseph Monahan Ph.D.
Chief Scientific Officer
Compensation
$492,432
Dr. Neal S. Walker D.O., M.D.
Co-Founder, Chief Executive Officer & Chairman
Compensation
$874,633
Mr. Steve Tucker
Executive Vice President of Project Leadership
Mr. Matthew Rothman J.D.
General Counsel & Corporate Secretary
Dr. Hugh M. Davis Ph.D.
President, Chief Operating Officer & Director
Compensation
$555,541
Dr. Jon Jacobsen Ph.D.
Senior Vice President of Chemistry
Mr. Ajay Aggarwal M.B.A., M.D.
Senior Vice President of Clinical Development
Mr. William C. Roberts
Senior Vice President of Corporate Communications & Investor Relations
Aclaris Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $1.36M worth of ACRS shares, with no buying activity reported.
3 Months
0
0.00
300.0K
1.36M
-1.4M
-$1.36M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Leonard Braden Michael
10 Percent Owner
$1.36M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.36M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
SEC Filings
ACRS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 04, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 20, 2023 | April 20, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 22, 2021 | June 03, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 23, 2020 | June 04, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 25, 2019 | June 06, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 26, 2018 | June 07, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 21, 2017 | June 15, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.